Immune Tolerance Network   A clinical research consortium sponsored by NIAID and JDRF
START logoA clinical research study of thymoglobulin to arrest type 1 diabetes


Participating in the START trial

Qualified individuals who are interested in participating in the START trial will be asked to attend a screening appointment to further assess whether you are a good fit for this trial. If the screening process indicates that you are eligible and you decide to participate, you will be enrolled as a volunteer in the trial.

At the beginning of the trial, you (or your child) will stay in the hospital for 5-8 days to receive the study treatment (or placebo).

All participants in the START trial will receive, at no cost to themselves:

  • participation in an intensive diabetes management program
  • access to study doctors or nurses to discuss questions and concerns
  • regular counselling with diabetes educators
  • regular physical exams
  • regular laboratory testing to assess diabetes progression
  • a complimentary blood glucose monitor and supplies for the duration of the study

Some compensation is also available: START staff will provide more details at your request.

Participants will also be asked to attend several appointments over a period of 2 years.

Who can Participate?

To be eligible to for the START trial, you or your child must be between the ages of 12-35 years old and diagnosed with type 1 diabetes within the last 3 months. To be eligible to participate in the START trial, you must:

  • be aged 12-35
  • have been diagnosed with type 1 diabetes within the past 3 months

If you believe you may be eligible to participate, contact a clinical site nearest you for more information.

Recruitment is now closed.

For information on additional ITN trials for people recently diagnosed with type 1 diabetes, please visit:

Retain Study

T1DAL Study



START Brochure (871 kb)

FAQ (438 kb)

Physician Reference Card (154 kb)

Do you have questions? Contact us or read the FAQ.

Terms of Use | Privacy | Accessibility
©2007, Immune Tolerance Network